Form 4: Vericel CMO Sells Shares Under 10b5-1 Plan

Vericel's Chief Medical Officer, Jonathan Hopper, sold 1,652 shares of common stock for $39.14 per share, following an option exercise, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp, executed a transaction involving company common stock.
• On December 2, 2025, Hopper acquired 1,652 shares of common stock by exercising stock options at a price of $18.00 per share.
• Concurrently, on December 2, 2025, he sold 1,652 shares of common stock at a price of $39.14 per share.
• The sale was conducted automatically pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025.
• Following these transactions, Hopper's direct beneficial ownership of common stock is 66,562 shares.
• He also holds 7,098 remaining stock options.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider transaction (option exercise and sale) by a Chief Medical Officer. Such transactions are generally neutral in sentiment as they are part of executive compensation and personal financial planning, especially when conducted under a 10b5-1 plan.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent sale rather than an immediate reaction to new information.
• The sale price of $39.14 per share is significantly higher than the exercise price of $18.00 per share, indicating a profitable transaction for the officer.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the amount here is relatively small compared to total holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2025.

Industry Context

This filing details a routine insider transaction by a Chief Medical Officer, which is common in the biotechnology and medical device industry for executive compensation and personal financial planning. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• Insider transactions, particularly those executed under Rule 10b5-1 plans, are standard practice for executives in publicly traded companies across various industries, including biotech and pharmaceuticals. These plans are designed to allow insiders to sell shares without being accused of trading on material non-public information. The size of this transaction is relatively small and typical for routine liquidity management by an executive.

Related Party Transactions

• The transaction involves an executive officer of Vericel Corp selling company stock, which is inherently a related party transaction.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares by a Chief Medical Officer under a pre-arranged plan is unlikely to have a significant direct impact on the company's stock price or long-term shareholder value. It represents a routine liquidity event for an executive.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the execution of the pre-planned trade.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction by a Chief Medical Officer, involving the exercise of options and subsequent sale of shares. Such transactions, especially when executed under a Rule 10b5-1 plan, are typically for personal financial planning and executive compensation, and do not usually signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Vericel Corp, VCEL, Jonathan Hopper, Chief Medical Officer, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Equity Transaction